Ningxia Medical University to Transfer Patent for Antidepressant Polysaccharide Lyophilized Powder Derived from Stellaria dichotoma for RMB 40,000
Recently, Ningxia Medical University released a public notice on the conversion of scientific and technological achievements, proposing to"A Polysaccharide Lyophilized Powder with Antidepressant Effects, and Its Preparation Method and Application"The relevant patents have been transferred to Xinjiang Huachun Biopharmaceutical Co., Ltd., with a proposed transfer amount ofRMB 40,000。
This patent relates to a polysaccharide lyophilized powder with antidepressant effects, as well as its preparation method and applications. The core innovation lies inPreparation of Lyophilized Powder from Polysaccharides Extracted from the Natural Medicinal Herb Stellariae Radix, overcoming the industry pain point of significant side effects associated with existing clinical antidepressant medications, which often lead to patient discontinuation due to intolerance, throughAqueous Extraction and Ethanol Precipitation, Protein Removal by Redissolution, Concentration and LyophilizationThe freeze-dried powder of polysaccharides from Stellaria dichotoma var. lanceolata, prepared through a proprietary process, is natural, safe, and free of serious side effects. Animal experiments have confirmed its clear and significant antidepressant efficacy. Its mechanism of action involves regulating the levels of monoamine neurotransmitters in the brain and normalizing the negative feedback function of the hypothalamic-pituitary-adrenal (HPA) axis, thereby providing a novel natural product direction for the development of antidepressant drugs.
Depression is one of the most common mental disorders in current clinical practice. Its clinical manifestations are diverse and complex, with core symptoms characterized by persistent low mood, feelings of inferiority marked by self-denial, anhedonia (loss of pleasure), and a state of hopelessness regarding life. Some patients also present with comorbid symptoms such as anxiety. In severe cases, patients may exhibit suicidal ideation or engage in suicidal behaviors, posing a serious threat to their safety and well-being.
Moreover, this disease is characterized by significant recurrence, with a protracted and refractory course. It imposes long-term and severe psychological and physiological impairments on patients, substantially diminishing their quality of life and exerting numerous adverse effects on their family and social functioning, thereby posing substantial harm to both physical and mental health. With the rapid development of the socio-economy, escalating competitive pressures in daily life have led to an increase in psychological stressors, resulting in a rapidly rising incidence of depression. Consequently, it has become a public health issue that urgently requires societal attention and intervention.
In the clinical treatment of depression, due to the complex pathogenesis and high recurrence rate of the disease, patients often require long-term pharmacotherapy, resulting in a relatively prolonged overall treatment course.Ongoing Efficacy and Safety of the Drugbecome the key to treatment. Currently, the antidepressant regimens commonly used in clinical practice are still dominated by chemically synthesized Western medicines, primarily including selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and heterocyclic antidepressants. Although these medications can alleviate depressive symptoms to some extent, they are generally associated with various significant adverse effects that impose an additional burden on patients’ physical health. For instance, they may trigger hypertensive crises, exacerbate hypomanic symptoms, cause decreased libido, and induce serotonin toxicity, leading to a series of discomforts such as mania, agitation, and insomnia.
Clinical survey data indicate that a significant proportion of patients taking antidepressants are forced to discontinue medication due to intolerance of the associated side effects. This not only directly compromises the efficacy of depression treatment, leading to relapse or even exacerbation of the condition, but also increases the difficulty of subsequent therapeutic interventions, representing a major challenge in the clinical management of depression.
Against this backdrop, the clinical demand for novel antidepressants with proven efficacy and reduced side effects has become increasingly urgent. Overcoming the limitations of existing chemically synthesized drugs by identifying and extracting active ingredients with potent antidepressant effects from natural products, and developing antidepressants with higher safety profiles and better tolerability to meet the long-term medication needs of patients with depression, has emerged as a critical research challenge for professionals in the pharmaceutical industry. This endeavor also represents a core direction driving innovation and development in the field of antidepressant drug research and development.
This technology for freeze-dried powder of polysaccharides from Stellaria dichotoma, which exhibits antidepressant effects, achieves significant innovation in the field of antidepressant drugs by leveraging the core principles of natural product development. It offers notable advantages in terms of raw materials, manufacturing processes, efficacy, and safety, thereby overcoming many limitations associated with conventional Western antidepressants.
The core innovation of this technology lies in its first-time integration ofStellaria RootThis traditional Chinese medicinal material serves as the core raw material for extracting polysaccharides to prepare an antidepressant freeze-dried powder. This approach fully leverages the pharmaceutical value of natural herbs, ensuring that the active antidepressant ingredients are derived from natural sources and safeguarding medication safety at the raw material level. Experimental verification has confirmed that this component is non-toxic and does not cause severe adverse drug reactions, thereby addressing a critical clinical challenge associated with conventional Western antidepressants, which often trigger multiple adverse effects.
InPreparation Processabove, the technology was designedAqueous extraction and ethanol precipitation, collection of precipitate, resolubilization and protein removal, concentration and freeze-dryingThe exclusive preparation process also achieves efficient extraction and purification of *Stellaria dichotoma* polysaccharides by optimizing key process parameters, including the solid-to-liquid ratio, extraction time, concentration temperature, and centrifugation conditions. This approach not only enhances the yield of polysaccharide precipitation but also ensures the effective content of polysaccharides in the freeze-dried powder. The process steps are scientifically standardized and highly operable, laying a solid foundation for industrial-scale translation.
InPharmacological EfficacyAt the level of, the technology's R&DLychee Polysaccharide Lyophilized Powder Has Clear and Significant Antidepressant Effects, validated through animal experiments, it can effectively improve depression-related behavioral manifestations, andNo additional central nervous system stimulant or depressant effects, while exerting antidepressant effects, it does not affect the body's spontaneous activity, demonstrating excellent therapeutic efficacy.
And inMechanism of Actionabove, this technologyAchieved an Innovative Breakthrough in Dual Regulation, Stellaria dichotoma polysaccharides can not only effectively regulate the levels of monoamine neurotransmitters in the brain and restore the normal levels of related neurotransmitters and metabolic enzymes in key brain regions such as the hippocampus and cortex, but also reconstruct the normalized negative feedback function of the HPA axis and reverse the abnormal elevation of glucocorticoids in depression models, fromNeurotransmitter RegulationandEndocrine System RepairExerting antidepressant effects through two dimensions, with clear and comprehensive mechanisms of action, it provides novel therapeutic targets and research directions for the development of antidepressant drugs.
Furthermore, this technology clarifies the direct application value of *Bupleurum scorzonerifolium* polysaccharides in the development of antidepressant medications. The research outcomes can be directly integrated into industrial-scale pharmaceutical production, providing a novel natural therapeutic option for clinical depression treatment. This advancement fills a gap in the research and development of natural product-based antidepressants, demonstrating both clinical utility and potential for industrial translation.
Lyophilized Powder of Stellaria dichotoma Polysaccharides, belonging to the category of natural plant-derived antidepressants, boasts promising market prospects driven by evolving market demands, supportive policy directions, and its inherent technological advantages. With the continuously expanding population of patients with depression, there is an increasingly urgent clinical demand for antidepressants with low side effects and high safety profiles. The adverse reaction issues associated with traditional chemical drugs have created substantial market space for natural product-based antidepressants, laying a solid foundation for their clinical application and market promotion.
Currently,Modernization of Traditional Chinese Medicinebecoming an important guide for the pharmaceutical industry,Natural Plant-Derived DrugsLeveraging its natural raw materials and safety profile, it aligns with the current trend toward healthier pharmaceutical consumption, thereby gaining policy support and market recognition. Stellaria dichotoma polysaccharide lyophilized powder is derived from authentic Chinese herbal medicines, features mature manufacturing processes and a clearly defined mechanism of action, and has demonstrated definitive antidepressant efficacy through experimental validation. These attributes establish its technological and therapeutic advantages, providing a solid foundation for industrialization.
Traditional Small-Molecule Antidepressantsare currently the mainstream category in clinical antidepressant therapy, primarily includingSelective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic and Heterocyclic Antidepressantsand so on, relevant patents and industrialization technologies have matured. Among them, selective serotonin reuptake inhibitors (SSRIs), as the mainstream medication, are widely used in clinical practice and highly prevalent, serving as the first-line choice for depression treatment at this stage. Although tricyclic and heterocyclic antidepressants have a long history of application, their clinical use is increasingly limited due to adverse reactions. Monoamine oxidase inhibitors (MAOIs) are used only in special cases due to clear contraindications. Meanwhile, with the market’s growing demands for drug safety and tolerability, the side effects of traditional chemical drugs have become a significant constraint on industry development, posing new challenges to the market growth of these medications.
Morinda officinalis Oligosaccharide Capsules: China’s First Natural Oligosaccharide-Based Traditional Chinese Medicine Antidepressant (Class 5 New Drug), byBeijing TongrentangAs a benchmark product among natural product-based antidepressants developed and manufactured in-house, it features oligosaccharides from Morinda officinalis as its core active ingredient. It exerts antidepressant effects by modulating neurotransmitters in the brain, primarily targeting the treatment of mild to moderate depression. With a high safety profile and low incidence of side effects, it is suitable for special populations with restrictions on conventional chemical drug use, such as adolescents and postpartum women, as well as for general patients who have low tolerance for the side effects of conventional chemical drugs. In terms of market application, the drug enjoys high clinical recognition, has been included in multiple guidelines and expert consensus statements on the diagnosis and treatment of depression, and is widely used in psychiatric departments, traditional Chinese medicine departments, and maternal and child health hospitals. It can be administered as monotherapy or in combination with conventional chemical drugs.
The prevalence of depression continues to rise, creating an increasingly urgent clinical demand for antidepressants with low side effects and high safety profiles. The adverse reaction profile associated with traditional chemical drugs has left considerable market space for natural product-based antidepressants, laying the foundation for their clinical application and market promotion.